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Abstract
Introduction: Although a substantial proportion of male breast cancers (MBCs) are hereditary, the molecular
pathways that are activated are unknown. We therefore examined the frequency and clinicopathological
associations of the PIK3CA/mammalian target of rapamycin (mTOR) and mitogen-activated protein kinase (MAPK)
pathways and their regulatory genes in familial MBC.
Methods: High resolution melting analysis and confirmatory sequencing was used to determine the presence of
somatic mutations in PIK3CA (exon 9 and 20), AKT1 (exon 4), KRAS (exon 2) and BRAF (exon 15) genes in 57 familial
MBCs. Further analysis of the PIK3CA/mTOR pathway was performed using immunohistochemistry for the pAKT1,
pS6 and p4EBP1 biomarkers.
Results: PIK3CA somatic mutations were identified in 10.5% (6 of 57) of cases; there were no AKT1, KRAS or BRAF
somatic mutations. PIK3CA mutations were significantly more frequent in cancers from BRCAX patients (17.2%, 5/29)
than BRCA2 (0%, 0/25) carriers (P = 0.030). Two BRCAX patients had an E547K mutation which has only been
reported in one female breast cancer previously. PIK3CA mutation was significantly correlated with positive pS6
(83.3% vs. 32.0%, P = 0.024) and negative p4EBP1 (100% vs. 38.0%, P = 0.006) expression, but not pAKT expression.
Expression of nuclear p4EBP1 correlated with BRCA2 mutation carrier status (68.0% vs. 38.7%, P = 0.035).
Conclusions: Somatic PIK3CA mutation is present in familial male breast cancer but absent in BRCA2 carriers. The
presence of two of the extremely rare E547K PIK3CA mutations in our cohort may have specific relevance in MBCs.
Further study of PIK3CA in MBCs, and in particular BRCAX patients, may contribute to further establishing the
relevance of specific PIK3CA mutations in MBC aetiology and in the identification of particular patient groups most
likely to benefit from therapeutic targeting with the novel PIK3CA inhibitors that are currently in development.
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Introduction
Recent studies characterising male breast cancer (MBC)
show that these rare tumours are very different to their
female counterparts [1,2]. In particular, there are notable
distinctions between familial female and MBC with a dif-
ferent pattern of penetrance and genotypic phenotypic
correlation in BRCA1, BRCA2 and BRCAX subsets [1].
While it is likely that hormonal influence is a significant
contributor, as yet, the characterisation of oncogenic dri-
vers by mutation analysis of even the most common gene
mutations in MBCs has not been undertaken.
Several significant targetable oncogenes are known and
relatively well described in female breast cancer (FBC).
The most frequent gain of function mutations is seen in
phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic
subunit alpha 9 (PIK3CA) which forms one of the cataly-
tic subunits of the phosphatidylinositol 3-kinase (PI3K)
holoenzyme [3,4]. Mutations of the helical or kinase
domain lead to activation of the p110a kinase with subse-
quent downstream triggering of the mammalian target of
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rapamycin (mTOR) leading to cell proliferation, angio-
genesis and promotion of the metastatic process [5,6].
Additional regulators of the PIK3CA/mTOR pathway
include AKT1 and the RAS/RAF/mitogen-activated pro-
tein kinase (MAPK) pathway that intersect at multiple
points [7-13].
Within FBC, the prevalence and prognostic significance
of tumours with these driving mutations are unclear and
may be dependent on both tumour histological type and
estrogen receptor (ERa) status [14-17]. Notably, in vitro
studies propose that activation of the PIK3CA/mTOR
pathway may be important in tumours with deficient
homologous recombination [18], suggesting a possible role
in gaining resistance to poly ADP ribose polymerase
(PARP) inhibitors in BRCA1/2 deficient tumours. How-
ever, although there are limited data (n = 22), an associa-
tion between BRCA1/2 loss and activation of the PIK3CA/
mTOR pathway in human tumours has not been con-
firmed [15].
Despite accruing data in FBC as to the significance of
these oncogenes, there are few studies examining somatic
mutation in sporadic MBC only [19-23], with the major-
ity of studies focused on gene expression profiling
[24-26] and germ-line mutational analysis [27-32].
Since the PIK3CA/mTOR pathway is more frequently
associated with ERa positive FBC, and MBC is largely
characterised by ERa positive disease, we have examined
the frequency of activation of the PIK3CA/mTOR pathway
and its regulators in a cohort of 57 familial MBCs. While
the reported frequency of KRAS and BRAF mutations in
female breast cancer is generally low (<5%) reference
[33,34], a single sporadic MBC study showing a markedly
high percentage of KRAS mutations (12%) also encouraged
investigation of the mitogen-activated protein kinase
(MAPK) pathway, which also interacts with the PIK3CA/
mTOR pathway. Our aims were to; (1) identify PIK3CA,
AKT1, KRAS and BRAF mutations in familial male breast
cancer, (2) assess the relationship between such somatic
gene mutations and clinicopathological factors, including
BRCA1/2 mutation carrier status, and (3) identify and
characterise the PIK3CA/mTOR and MAPK pathway and
correlate with any clinicopathological factors and survival.
Materials and methods
Patient samples
Only primary breast cancers were examined in this study.
Cases were obtained from the kConFab repository [35].
Prerequisites for cases to be included into kConFab are a
strong family history of breast and ovarian cancer (Breast
and Ovarian Analysis of Disease Incidence and Carrier
Estimation Algorithm (BOADICEA) scores [36] generated
from family pedigree and stratified by BRCA1/2 mutation
carrier status included as Additional file 1: Supplementary
figure 1) with criteria for admission to the kConFab study
as outlined previously [37]. Cases were from Australia and
New Zealand and diagnosed between 1980 and 2009.
The flow of patients through the study according to the
REMARK criteria [38] is listed in Additional file 2: Sup-
plementary table 1. Of the 118 cases within the kConFab
registry, 58 cases were excluded due to unavailability of
tissue. Of the 60 cases where tissue was available, 2 cases
had insufficient tumour tissue for DNA extraction or for
a core to be taken for assembly of a tissue microarray
(TMA) and a further single case had an extremely low
DNA yield and insufficient material for tissue microarray.
Fifty seven cases had sufficient material at an appropriate
DNA concentration for somatic mutation testing and
one case did not have adequate tissue for TMA construc-
tion with all tissue committed to DNA extraction. Clini-
cal parameters, including disease specific mortality were
obtained from referring clinical centres, kConFab ques-
tionnaires and state death registries. Information on pedi-
gree, mutational status and testing were available from
the kConFab central registry. Histological classification
was based on criteria set by the World Health Organiza-
tion 2012 [39] and all slides and pathological records
from all cases were reviewed for tumour size, tumour
grade, lymphovascular and perineural invasion. Immuno-
histochemistry for ERa, progesterone receptor (PgR),
basal markers (cytokeratin (CK) 5, epidermal growth fac-
tor receptor (EGFR)) and HER2 silver in situ hybridisa-
tion (SISH) had been performed as previously reported
[1]. Using stratification of intrinsic phenotypes based on
Nielsen et al. [40], tumours were placed into luminal
(ERa positive, HER2 negative, CK5 and/or EGFR nega-
tive or positive), basal (HER2 and ERa negative; CK5
and/or EGFR positive), HER2 (HER2 positive, ERa, CK5
and EGFR negative or positive) and null/negative (HER2,
ERa, CK5 and EGFR negative) phenotypes. This work
was carried out with approval from the Peter MacCallum
Cancer Centre Ethics Committee (Project No: 11/61).
The approval included waiver of patient consent.
Germline BRCA1/2 testing
Mutation testing for BRCA1 and BRCA2 mutations was
performed as reported previously [1]. Testing of index
cases in kConFab families was carried out by denaturing
high performance liquid chromatography or multiplex
ligation-dependent probe amplification. Once the family
mutation had been identified, all pathogenic (including
splice site) variants of BRCA1 and BRCA2 were geno-
typed by kConFab in all available family members’ DNA.
High-Resolution Melting (HRM) assay
Genomic DNA was extracted from formalin-fixed, paraf-
fin embedded (FFPE) samples. A 3 μM haematoxylin
and eosin (H&E) stained slide was cut from FFPE blocks
and stained to identify tumour enriched areas. From the
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relevant area on the FFPE block, a 2 mm punch biopsy
core was taken. The cores were then dewaxed and
hydrated through gradient alcohol. Genomic DNA was
then extracted using the DNeasy Tissue kit (Qiagen,
Valencia, CA, USA)) following proteinase K digestion at
56°C for three days.
The PIK3CA, AKT1, BRAF and KRAS primer sequences
are shown in Additional file 3: Supplementary table 2.
PIK3CA exon 9 and 20 primers produced amplicons with
104 base pairs (bp) and 102 bp, respectively. AKT1 exon 4,
BRAF exon 15 and KRAS exon 4 primers produced 78 bp,
144 bp and 92 bp amplicons, respectively. PCR for HRM
analysis was performed in 0.1 ml tubes on a Rotor-Gene
Q (Qiagen) utilising the fluorescent DNA intercalating
dye, SYTO 9 (Invitrogen, Carlsbad, CA, USA). A 20 μL
final reaction volume contained 1 × PCR buffer, 0.5 to
2.0 mM MgCl2, 200 to 400 nM of forward and reverse
primer, 200 μM of dNTPs, 5 μM of SYTO 9, 0.5 U of
HotStarTaq polymerase (Qiagen), 5 ng of genomic DNA,
Uracil-DNA glycosylase (UDG) (0.5 units/reaction), UDG
buffer (New England BioLabs, Ipswich, MA, USA) and
PCR grade water. The cycling and melting conditions are
shown in Additional file 3: Supplementary table 2. All
reactions had initial UDG treatment for FFPE artefacts at
37°C for 30 minutes [41], followed by an incubation step
at 95°C for 15 minutes, denaturation step at 95°C, anneal-
ing steps at the temperatures listed in Additional file 3:
Supplementary table 2, and an elongation step at 72°C. A
single cycle of 97°C for one minute preceded a melt phase
run between temperatures listed in Additional file 3: Sup-
plementary table 2 and rising 0.2°C per step. Samples were
run in duplicate. HRM analysis was performed on the
Rotor-Gene Q Software (v1.7) (Qiagen, Valencia, CA,
USA).
DNA sequencing
All samples with either or both duplicates showing
abnormal melt were sequenced for detection of muta-
tions. PIK3CA exon 9 and 20 HRM products were
amplified using M13 tagged primers (Additional file 3:
Supplementary table 2) initially and then M13 primers
for a second step for PIK3CA exon 9 (amplicon 185 bp)
and a single step PCR reaction for PIK3CA exon
20 (amplicon 149 bp) using primers listed in Additional
file 3: Supplementary table 2. The composition of a total
reaction mixture of 20 μL contained; 1 × PCR buffer,
2.5 mM MgCl2, 400 nM of each primer, 200 μM of
dNTPs, 0.5 U of HotStarTaq polymerase (Qiagen), 5 ng
of HRM DNA products and PCR grade water. The PCR
conditions were as follows: an initial incubation at 95°C
for 1 minute, followed by 35 cycles of 95°C for 10 seconds,
55°C for 10 seconds and 72°C for 4 minutes. The sequen-
cing reaction was then performed using the Big Dye
Terminator v3.1 chemistry according to the manufac-
turer’s protocol (Applied Biosystems, Foster City, CA,
USA) using 6 μL of the PCR products that were purified
with 2 μL of ExoSapIT (GE Healthcare, Little Chalfont,
Buckinghamshire, UK). After ethanol precipitation, the
sequencing products were run on a 3700 Genetic Analyser
(Applied Biosystems). The sequencing data were then ana-
lysed using Sequencher 4.6 (Gene Codes Corporation,
Ann Arbor, MI, USA). Each mutation was confirmed by
sequencing a second independent PCR reaction. The work
flow is outlined in Figure 1.
Immunohistochemistry
Tumour-tissue microarrays (1-mm cores), with a two-
fold redundancy, were prepared from archival FFPE tis-
sue blocks. TMA sections were cut from each block at
4 μm thick intervals, dewaxed, placed through graded
alcohol and then into water.
For phosphorylated 4EBP1 (p4EBP1) and phosphory-
lated S6 (pS6), antigen retrieval was performed using
high pH antigen retrieval buffer (DAKO, Glostrup,
Denmark) in pressure cooker for three minutes at 125°C.
For phosphorylated AKT1 (pAKT), antigen retrieval was
performed with CC1 high pH retrieval solution (Roche,
Basel, Switzerland) at 100°C for 36 minutes. Staining for
p4EBP1 (dilution 1:400, clone 2855, Cell Signalling Tech-
nology, Danvers, MA, USA) and pS6 (dilution 1:200,
clone 2211, Cell Signalling Technology) was performed
using a monoclonal and polyclonal rabbit antibodies
respectively. Antigen-antibody complex was detected
using the Envision FLEX system (EnVision FLEX/HRP
and EnVision FLEX DAB + Chromogen, DAKO). Stain-
ing for pAKT1 (dilution 1:1,000, clone LP18, Novocastra,
Newcastle upon Tyne, UK) was performed using a mono-
clonal mouse antibody with secondary detection using
Ventana Ultraview detection reagents (Roche). Slides
were then counterstained with haematoxylin, dehydrated,
cleared and mounted for assessment. Phosphorylated
4EBP1 expression was assessed for both cytoplasmic and
nuclear expression, nuclear expression for pAKT1 and
cytoplasmic expression for pS6 (Figure 2a). A histoscore
was generated by multiplying staining intensity (0, no
staining; 1, weak; 2, moderate; 3, strong) by the percen-
tage of positive tumour cells (0, 0; 1, < or = to 25%; 2,
>25% to 50%; 3, >50% to 75%, 4, >75%). The histoscores
ranged between 0 and 12. For subsequent analysis, histo-
scores were categorised into either absent (histoscore =
0) or present (1 to 12) or low (0 to 3) and high (4 to 12)
to differentiate from baseline staining of adjacent normal
breast epithelium.
A PIK3CA mutation phenotype was defined by either
a tumour harbouring a somatic PIK3CA activating
mutation or showing an absence of p4EBP1 expression
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and moderate to strong pS6 expression (histoscore 4-12/
12) on immunohistochemistry.
Statistical analysis
Comparison of groups was made using Mann-Whitney
U for non-parametric continuous distributions and chi-
square test for threshold data. Kaplan-Meier survival
curves were plotted using breast cancer related death as
the endpoint and compared using a log rank test. Analy-
sis was performed with GraphPad Prism 5 software
(GraphPad Prism version 5.04 for Windows, GraphPad
Software, La Jolla, CA, USA). A two-tailed P-value test
was used in all analyses and a P-value of less than 0.05
was considered statistically significant.
Results
PIK3CA is commonly mutated in familial male breast
cancer
Seven PIK3CA mutations were identified and confirmed
in six samples (Table 1). Four activating mutations were
Figure 1 Work flow of sample analysis. Initial High-Resolution Melting (HRM) analysis was used to screen mutation by abnormal melt. Sanger
sequencing was then performed to detect specific mutations.
Figure 2 PIK3CA/mTOR pathway (# 4EBP1 is inactivated by phosphorylation) a). Immunohistochemistry was performed for phosphorylated
AKT, pS6 and p4EBP1. b) Outcome of immunohistochemical staining integrating PIK3CA mutation status. Numbers indicate the amount of cases
showing positive immunohistochemical staining. Mutations are signified by (n*), with n = number of cases. mTOR, mammalian target of
rapamycin.
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identified in exon 9, with two cases of E547K mutation
and one sample demonstrated concurrent E542K and
E547K mutations in exon 9. Three further mutations
were identified in exon 20, all of which were H1047R
mutations. Screening of AKT1, BRAF and KRAS showed
no evidence of somatic mutations.
PIK3CA mutation is uncommonly seen in BRCA2 mutation
carriers
One tumour arising in a BRCA1 carrier had an exon 20
PIK3CA mutation, five PIK3CA mutations occurred in
BRCAX males whereas no PIK3CA mutation were identi-
fied in tumours from BRCA2 mutation carriers. There was
a significant positive association between PIK3CAmutation
incidence and BRCACX (17.2%) compared with BRCA2
(0%) associated tumours (P = 0.030). There was otherwise
no correlation between the presence of somatic PIK3CA
mutation and age of diagnosis, primary tumour size, tumour
histological subtype, tumour grade, intrinsic phenotype,
lymphovascular or perineural invasion (P > 0.05) (Table 2).
The presence of PIK3CA mutation was not associated with
a significant difference in Disease Specific Survival (DSS)
(Figure 3).
Co expression and clinicopathological correlation of
p4EBP1, pS6, pAKT biomarkers
Cytoplasmic expression of p4EBP1 was present (histoscore
1 to 12) in 55.4% (31/56) of cases, nuclear p4EBP1 expres-
sion (histoscore 1 to 12) in 51.8% (29/56) of cases and
either nuclear or cytoplasmic expression in 58.9% (33/56)
of cases. High expression of both pS6 and pAKT1 (histo-
score 4 to 12) was seen in 37.5% (21/56) of cases each. A
pattern of co-expression of any of the markers was not
seen (P > 0.05) (Figure 2b). Clinicopathological correlation
showed that nuclear expression of p4EBP1 correlated with
BRCA2 carrier status (17/25 (68.0%) P = 0.035) and inver-
sely with BRCAX cases (11/30 (36.7%) P = 0.0184). There
was no correlation between DSS and expression of any
markers (Additional file 4: Supplementary figure 2).
PIK3CA mutation phenotype
All tumours with PIK3CA mutation showed differences in
some downstream pathway members. Expression of
Table 1 Somatic PIK3CA mutations in familial male breast
cancer
Nucleotide change Amino acid change BRCA status
c.1624G>A p.E542K BRCAX
c.1639G>A p.E547K BRCAX
c.1624G>A, c.1639G>A p.E542K, p.E547K BRCAX
c.3140A>G p.H1047R BRCAX
c.3140A>G p.H1047R BRCAX
c.3140A>G p.H1047R BRCA1 del exons 21_24






type (n = 51)
P-value
Age - mean (years) 62.2 63.0 0.899
Overall DSS 33.3% 33.3% 1.000
Carrier mutation status
BRCA1 1 2 0.288
BRCA2 0 25 0.030
BRCAX 5 24 0.194
Primary tumour size (mm) 18.8 19.1 0.948
Histological type
Invasive carcinoma - no





Invasive Papillary Carcinoma 0 3 1.000
Invasive Lobular Carcinoma 0 2 1.000
Tumour grade
1 0 3 1.000
2 3 26 1.000
3 3 22 1.000
Lymphovascular invasion 33.3% 39.2% 1.000
Perineural invasion 50.0% 41.2% 0.689
Intrinsic subtype
Luminal 6 45 1.000
HER2 0 5 1.000
Basal 0 1 1.000
Null 0 0 1.000
P-values < 0.05 in bold text.
Figure 3 Correlation of PIK3CA mutation and disease specific
survival.
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p4EBP1, pS6 and pAKT was observed in 0/6 (0%), 5/6
(83.5%) and 2/6 (33.3%) of cases respectively (Figure 2b).
There was significant absence of p4EBP1 nuclear (P =
0.009) or cytoplasmic (P = 0.006) staining and up-regulation
of pS6 (P = 0.024) in tumours with PI3KCA somatic muta-
tions when compared with PIK3CA wild type (Table 3).
Discussion
This study is the first to characterise biomarkers and
mutations in the PIK3CA/mTOR pathway in familial
male breast cancer noting several novel observations.
We identified a PIK3CA mutation rate of 10.5% in
familial MBCs but an absence of common activating
mutations of AKT1, KRAS and BRAF. While limited by
moderate numbers in our study, the absence of KRAS
mutation contrasts with the only other study performed
in sporadic MBCs by Dawson et al. who reported an
overall incidence of 12% [20]. Methodological reasons
may be underlying these difference but in our experi-
ence, HRM is a highly sensitive and robust technique
[42,43]. The absence of BRAF mutation is also some-
what expected and is supported by the stronger
association between basal cell breast cancer lines and
BRAF mutation [44] (since the majority of MBCs are of
a luminal subtype). While a true frequency of these
mutations requires further testing in a much larger
cohort, these data suggest frequency is unlikely to be
high and should parallel the range (0.7 to 5%) that is
observed in female breast cancer.
The mutation rate of PIK3CA in this series is lower
than the reported 17.9% (7/39) in the only other study
performed, although this was in a population-based
cohort of MBCs patients [19]. It is also less frequent
than that reported in FBC (16.3% [19] to 40.0% [3])
(Table 4), which supports the notion that male breast
cancer is biologically different from female breast cancer
and that therapies that rely on the experience of the
female disease are likely to be suboptimal. Furthermore,
evidence from our data demonstrating that differences
in this PIK3CA/mTOR pathway is dependent on the
germline genotypes of male breast cancer, shows the
basis of male breast cancer in BRCA2 mutation carriers
is very different to that of BRCAX giving further cre-
dence to personalising breast cancer treatment whether
Table 3 Correlation of p4EBP1, pS6 and pAKT immunohistochemistry with BRCA status and clinicopathological factors
4EBP1 pS6 pAKT









PIK3CA Mutation 0 6 0 6 5 1 2 4
PIK3CA Wild-Type 31 19 0.006 29 21 0.009 16 34 0.024 19 31 1.000
Carrier mutation status
BRCA1 1 2 0.581 1 2 0.605 1 2 1.000 0 3 0.284
BRCA2 15 10 0.596 17 8 0.035 9 16 0.582 10 15 0.786
BRCAX 15 13 0.456 11 19 0.018 11 17 1.000 11 17 1.000
Age - mean (years) 60.3 64.5 0.240 59.1 65.3 0.078 63.4 61.4 0.503 62.0 62.2 0.940
Primary tumour size (mm) 20.3 17.2 0.169 19.5 18.3 0.589 17.21 20.03 0.312 20.05 18.25 0.437
Histological type
Invasive carcinoma - no special type
(IC - NST)
21 19 0.563 22 19 0.766 13 28 0.212 15 26 1.000
IC-NST with micropapillary areas 6 3 0.716 3 6 0.288 6 3 0.066 3 6 1.000
Invasive Papillary Carcinoma 2 2 1.000 3 1 0.612 2 2 0.626 2 2 0.626
Invasive Lobular Carcinoma 2 1 1.000 1 1 1.000 0 2 0.523 1 1 1.000
Tumour Grade
1 2 1 1.000 2 1 1.000 2 1 0.549 1 2 1.000
2 16 13 1.000 16 13 0.789 9 20 0.409 11 18 1.000
3 13 11 1.000 11 13 0.590 10 14 0.591 9 15 1.000
LVI 40.7% 36.0% 0.781 28.0% 48.2% 0.163 31.8% 43.3% 0.565 33.3% 41.9% 0.780
PNI 51.7% 45.8% 0.575 40.7% 57.6% 0.436 36.4% 58.1% 0.166 33.3% 59.0% 0.093
Intrinsic subtype
Luminal 26 24 0.210 24 26 0.195 17 33 0.183 20 30 0.393
HER2 4 1 0.367 4 1 0.353 3 2 0.352 1 4 0.640
Basal 1 0 1.000 1 0 1.000 1 0 0.375 0 1 1.000
Null 0 0 1.000 0 0 1.000 0 0 1.000 0 0 1.000
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male or female using individual patient and tumour
characteristics. Thus, as the incidence of PIK3CA muta-
tions in tumours from in BRCA2 carriers is likely to be
negligible, these patients are unlikely to derive benefits
from the PIK3CA inhibitors that are now entering clini-
cal trials for female breast cancer [19].
The distribution of mutations of PIK3CA in male
breast cancer reported by Benvenuti et al. (Table 4)
showed exclusively exon 20 mutations in MBC, support-
ing the suggestion that the frequency of exon 9 and 20
mutations may be gender and tissue specific. We, how-
ever, noted an equal distribution of exon 9 and 20
mutations, which is more reflective of the distribution
seen by others in FBC [3,14]. Furthermore, the E547K
mutation noted in two of our BRCAX patients has only
once previously been reported in a single female breast
cancer suggestive of a unique hot spot preferentially
within male cancers. This mutation was detected and
confirmed using HRM and Sanger sequencing in dupli-
cate for each case using methodologies optimised for
FFPE material. We have extensive experience with this
methodology and feel it to be well suited and robust for
formalin fixed paraffin embedded material. While we
also acknowledge the occurrence of artifactual changes,
the E547K mutation has not been detected in over 300
FFPE tumour samples we have screened to date (unpub-
lished data) and thus, we feel that this mutation may be
particular to a subset of MBC. The E547K mutation
itself is found in the highly conserved helical domain of
PIK3CA and possibly confers increased catalytic activity.
The mutation is not unique to breast cancer, and has
also been reported previously in one colorectal adeno-
carcinoma [45] and in seven neuroendocrine tumours of
the lung [46] lending support for a true pathogenic
mutation. Targeted sequencing of further MBC, and in
particular non-BRCA2 tumours, may help determine a
more accurate incidence and potential relevance of this
uncommon mutation. We also observed a case with two
concurrent exon 9 mutations, which has not been pre-
viously reported in MBC. While there is some sugges-
tion of a more aggressive phenotype or of tumour
heterogeneity in cases with dual PIK3CA mutations
[16,47,48], the clinical significance of this is also unclear
due to the infrequency of this observation.
Recent data show that BRCA2 appears to be a signifi-
cant driver in MBC, with a considerably higher pene-
trance within male BRCA2 carriers compared with males
in BRCAX families and BRCA1 male mutation carriers
[1]. It is also noteworthy that BRCA2 somatic mutations
have also been reported in 21.8% of sporadic MBCs [22].
Furthermore, unlike in FBC, studies by Ottini et al. [49]
and ourselves [1] intimate a distinct BRCA2 phenotype in
MBCs, which more commonly contain areas of micropa-
pillary histology, are of a higher grade, are PgR negative
and are HER2 amplified. The genomic findings of this
study emphasize that BRCA2 tumours may be a distinct
subgroup in familial MBC and as such BRCA2 mutation
may be a significant driver in MBC. Further support for a
strong inherent BRCA2 associated drive independent of
gender and estrogenic influence in male breast cancer is
the association of PIK3CA mutation and ERa positive
female breast cancer [14-17], a phenotype which is com-
mon to BRCA2 associated male tumours (92%) [1], but
without the associated rate of PIK3CA mutation. These
data suggest that gender and hormonal dimorphism may
not be so significant in BRCA2 carriers and that BRCA2
male breast cancers align with the non-PIK3CA mutated
ERa positive group of female breast cancer.
PIK3CA oncogenic drive, however, may be more
important in non-BRCA2 MBCs where estrogenic influ-
ences may be more prominent. While our previous stu-
dies have shown that ERa and PgR positive tumours
Table 4 Comparison of PIK3CA mutation studies in male and female breast cancer
Male Breast Cancer Female Breast Cancer
Current
Study
Benvenuti S et al.
[20]
Benvenuti S et al.
[20]
Buttitta F et al. [14] Campbell IG et al.
[3]
Saal H et al. [16]
Study population High risk -
familial
Population based Population based Population based Population based Population based
Frequency 6/57
(10.5%)
7/39 (17.9%) 14/86 (16.3%) 46/180 (25.6%) 28/70 (40.0%) 77/292 (26.4%)
Mutation Locus 3 exon 9, 3
exon 20
7 exon 20 6 exon 9, 8 exon
20
23 exon 9, 23 exon 20 15 exon 9, 9 exon
20, 3 exon 7, 1
exon 6
31 exon 9, 49 exon


















carcinoma (46%, P < 0.001).
Exon 9 more frequently
seen in lobular carcinoma











P-values < 0.05 in bold text
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were seen at a similar frequency across all BRCA1,
BRCA2 and BRCAX cohorts and more commonly than
in FBC [1], based on this genotypic analysis, the
mechanism and effect of PIK3CA mutation is likely to
be different between the subgroups. Overall, given the
association between ERa positive tumours and increased
PIK3CA mutation frequency in FBC, one would assume
an increased rate of PIK3CA mutation in MBCs. This is
not seen and may suggest alternate receptor and
PIK3CA/mTOR interaction in male breast cancer or a
dose-based relationship differentiated by male cancers
with low estrogen at one end of the spectrum and
higher levels of estrogen in females at the opposite end.
While studies have extensively examined the correlation
between hormone receptor status and incidence of
PIK3CA mutation, as yet there are very limited data on
the effect of circulating oestradiol on PIK3CA mutation
rate with some suggestion that PIK3CA/mTOR activa-
tion may contribute to tamoxifen-resistance. Further
evidence of estrogen influence is also provided by Ben-
venuti et al. who observed a gender bias for PIK3CA
mutations in colorectal cancer with a higher incidence
of mutations in women (23%) compared with men (9%)
[19] (Table 4), which reflect the findings of our study.
Further study correlating serum oestradiol, testosterone
levels and PIK3CA mutation frequency in MBCs are
required to further elaborate on a possible association.
Recent in vitro studies showing increased sensitization
of cancers with defects in DNA homologous recombina-
tion (as seen in BRCA1/2 deficient cancers), to PARP
inhibition by targeting of PIK3CA [18,50] suggest that
PIK3CA/mTOR pathway interactions result in homolo-
gous recombination steady state. Support for the model
is not yet seen in vivo with only one study to date to have
examined a correlation between BRCA mutation carriers’
status and PIK3CA mutation incidence in FBC. Limited
by numbers, Michelucci et al. describe two mutations
(one codon 9 and one codon 20) in 12 BRCA2 mutation
carriers and no mutations in 10 BRCA1 mutation carriers
[15]. The clinical value of this dual targeting is unknown
in BRCA1/2 FBCs and whether it is male or female, this
study is also the first to describe a PIK3CA somatic muta-
tion in a BRCA1 mutation carrier. The low numbers of
MBCs in BRCA1 mutation carriers in our study reflects
the paucity of these tumours in this particular cohort,
and in BRCA1 carriers in general [51-54]. What is appar-
ent is that BRCA1-associated tumours in males appear to
be more similar to the tumours seen in post-menopausal
female BRCA1 carriers, with an absence of tumours aris-
ing in young patients and an absence of an association
with basal cell phenotype. Notwithstanding, carrying a
BRCA1 mutation does appears to be a risk factor for
MBC with a higher incidence than that of the general
population but at much lower penetrance than seen in
female BRCA1 carriers and it is still unclear as to the role
BRCA1 plays in MBC. While the findings in this study
are novel, true incidence and relevance of PIK3CA muta-
tions in this cohort require further investigation of larger
numbers of BRCA1 patients, if these can be acquired for
study.
The alignment of PIK3CA mutation with elevated pS6
expression and absent p4EBP1 expression is different to
the expected model. Theoretically, PIK3CA mutational
activation of the pathway should only lead to an ele-
vated pS6, as is seen, but not an elevated p4EBP1 (the
phosphorylated form being inactive) and pAKT, which
is not observed. This is in part likely to be due to the
complexity of the PIK3CA/mTOR pathway. Indeed, a
correlation between PIK3CA mutation in luminal A FBC
(the phenotype most similar to MBC) and combined up-
regulation of pAKT, p4EBP1 and pS6 is not seen [55].
The association seen in the series between PIK3CA
mutation and elevated pS6 (P = 0.024) may suggest par-
tial activation of the PIK3CA/mTOR pathway in MBC
and reflect the variability of pS6 and p4EBP1 and pAKT
levels seen in vitro with dose dependent inhibition of
mTORC1 [56], or interactions of mTORC2, other path-
ways and feedback loops.
Nevertheless, we observed up-regulation of p4EBP1 in
BRCA2 mutation carriers (68.0%) more frequently than
in BRCAX carriers (36.7%), an association not reported
in FBC, giving further evidence to the difference in male
and female breast cancers. It may be that an alternate
mechanism of PIK3CA/mTOR pathway activation may
be present in BRCA2 cases linked to disordered homolo-
gous recombination, as mentioned previously, through
p4EBP1 and eIF4e.
Conclusion
The results of this study indicate that somatic PIK3CA
mutation are a frequent alteration in familial MBC of
BRCAX families, the incidence and type of which is
comparable to that seen in sporadic male and slightly
lower than FBCs. Conversely, the absence of PIK3CA
mutation in BRCA2 associated MBCs suggests that
alternate oncogenic drivers minimally contribute to
tumour drive in this group, thus supporting distinct
male breast cancer types. The study has also revealed
differences of MBC to FBC and between sporadic and
familial MBC which are of importance in optimising
treatment strategies and underlying relevance of the
PIK3CA/mTOR pathway in tumour biology. Indeed, the
therapeutic implications of these findings support the
delineation of significant molecular pathways, such as
PIK3CA/mTOR and MAPK cascades for subsequent
targeted therapies within specific populations.
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Additional file 1: Supplementary figure 1: BOADICEA scores for
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cases recruitment.
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Additional file 4: Supplementary figure 2. Disease specific survival
stratified by 1a) nuclear p4EBP1 expression, 1b) cytoplasmic p4EBP1
expression, 1c) pS6 expression and 1d) pAKT expression.
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